Scribe Therapeutics vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series B. Jennifer Doudna co-founder. Sanofi + Eli Lilly partnerships. STX-1150 (PCSK9 silencing via CasX-ELXR) IND projected mid-2026 — no permanent DNA edits.
About
Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.